show that PIM1 (Montrer PIM1 Kits ELISA) contributes to melanoma cell proliferation and tumor growth in vivo; however, the presence of PIM2 and PIM3 (Montrer PIM3 Kits ELISA) could also influence the outcome.

the elevated expression of PIM2 in blastic cells is associated with poor prognosis of AML (Montrer RUNX1 Kits ELISA) patients and their resistance to induction therapy.

Our data provide evidence for a novel role for Pim2 in the regulation of the DNA damage response (DDR (Montrer DDR1 Kits ELISA)). Knockdown of Pim2 upregulates several downstream DDR (Montrer DDR1 Kits ELISA) markers, mimicking the effects of doxorubicin (Dox) treatment of MM cells, and suggesting a role for the kinase as a negative regulator of this pathway.

These results demonstrate the involvement of PIM (Montrer PIM1 Kits ELISA) kinases in LIF (Montrer LIF Kits ELISA)-induced regulation in different trophoblastic cell lines which may indicate similar functions in primary cells.

We show that Pim2 inhibitors and proteasome inhibitors, such as bortezomib, have additive effects to inhibit the growth of myeloma cells, suggesting that Pim2 could be an interesting target for the treatment of multiple myeloma.

Pim-2 and Akt-1 (Montrer AKT1 Kits ELISA) are critical components of overlapping but independent pathways, either of which is sufficient to promote the growth and survival of nontransformed hematopoietic cells

Proto-Oncogene Pim-2 (Serine Threonine Kinase) (PIM2) profil antigène

Antigen Summary

This gene encodes a protooncogene that acts as a serine/threonine protein kinase. Studies determined the encoded protein functions to prevent apoptosis and to promote cell survival.